Table 3.
Eradication rate during periods without (June, 2004 to October, 2005) and with (November, 2005 to March, 2011) a routine genetic test for CYP2C19
| Subjects | 2004–2005 | 2005–2011 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Untested n (%) |
*1*1 n (%) |
Other genotypes n (%) |
Untested* n (%) |
Total n (%) |
||||||
| Visited | 198 | 296 | ||||||||
| Examined** | 197 | (100) | 290 | (100) | ||||||
| Infected | 131 | (66.5) | 66 | 132 | 3 | 201 | (69.3) | |||
| Treated | 114 | 61 | 124 | 3 | 188 | |||||
| Succeeded*** | 72 | (80.0) | 53 | (100.0) | 74 | (83.1) | 1 | (50.0) | 128 | (88.9) |
| Failed*** | 18 | (20.0) | 0 | (0.0) | 15 | (16.9) | 1 | (50.0) | 16 | (11.1) |
| Not evaluated | 24 | 8 | 35 | 1 | 44 | |||||
| Re-treated | 12 | 0 | 14 | 1 | 15 | |||||
| Succeeded*** | 7 | (87.5) | 0 | 12 | (92.3) | 0 | 12 | (92.3) | ||
| Failed*** | 1 | (12.5) | 0 | 1 | (7.7) | 0 | 1 | (7.7) | ||
| Not evaluated | 4 | 0 | 1 | 1 | 2 | |||||
* Untested for CYP2C19 before prescription
** Examined for H. pylori infection
***The parencethese shows rates excluding those unevaluated